The demo achieved both its primary endpoints, with semaglutide two.4 mg demonstrating statistically major and exceptional advancements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH when compared with placebo.1Program checking of serum ca